Profile Name | NOTCH1 rearrange |
Gene Variant Detail | |
Relevant Treatment Approaches |
Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References | NOTCH1 rearrange | triple-receptor negative breast cancer | no benefit | MRK-003 + SCH772984 | Preclinical | Actionable | In a preclinical study, SCH772984 did not potentiate the growth inhibition effect of MRK-003 in triple receptor-negative breast cancer cells harboring NOTCH1 rearrangement in culture (PMID: 25104330). | 25104330 | NOTCH1 rearrange | triple-receptor negative breast cancer | sensitive | MRK-003 + Paclitaxel | Preclinical | Actionable | In a preclinical study, MRK-003 and Taxol (paclitaxel) worked synergistically to inhibit tumor growth in triple receptor-negative breast cancer xenograft models harboring NOTCH1 rearrangement, resulting in tumor regression (PMID: 25104330). | 25104330 | NOTCH1 rearrange | triple-receptor negative breast cancer | sensitive | MRK-003 | Preclinical | Actionable | In a preclinical study, MRK-003 inhibited growth of triple receptor-negative breast cancer cells harboring NOTCH1 rearrangement in culture and reduced tumor growth in xenograft models (PMID: 25104330). | 25104330 |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status |
---|